Eko Health Expands Clinical Advisory Board to Advance AI-Powered Disease Detection

Expansion brings together top clinical leaders to help scale Eko’s disease detection platform following major FDA clearances, reimbursement wins, and peer-reviewed publications

SAN FRANCISCO, Aug. 6, 2025 /PRNewswire/ — Eko Health, a leader in AI-powered cardiac and pulmonary care, announced the expansion of its Clinical Advisory Board to support the company’s mission to transform how heart and lung disease are detected and managed. The board will provide strategic guidance on Eko’s clinical research and implementation strategy, inform product development, and help ensure the company’s work continues to advance equitable access to early disease detection.

The Clinical Advisory Board is chaired by Dr. Steve Steinhubl, a cardiologist and Professor of Biomedical Engineering at Purdue University. Prior to Purdue, Dr. Steinhubl served as Director of Digital Medicine at the Scripps Translational Science Institute, where he led pioneering work in wearable health technologies and digital trials.

“Eko has transformed the stethoscope into a gateway for AI-powered disease detection,” said Dr. Steinhubl. “By unlocking clinical insights during routine exams, they’re shifting the paradigm for how and where cardiopulmonary disease is caught. This advisory board will help ensure those advancements reach the clinicians and patients who stand to benefit most.”

Expanded Clinical Advisory Board includes:

  • Dr. Steve Steinhubl (Chair) – Cardiologist, clinical trialist, and Professor of Biomedical Engineering at Purdue University.
  • Dr. Ankeet Bhatt – Cardiologist and clinical investigator at Kaiser Permanente San Francisco Medical Center and Division of Research; Adjunct Professor at Stanford University School of Medicine.
  • Dr. Antoine Keller – Cardiothoracic surgeon at Ochsner Lafayette General Hospital; Co-Founder and President of HeartSense.
  • Dr. Joanna Kmiecik – Family medicine physician; Education-Centered Medical Home Lead/Preceptor at Northwestern University Feinberg School of Medicine and Medical Director at Oak Street Health.
  • Dr. Jennifer Kwan – Cardiologist and physician-scientist at Yale University; Assistant Professor of Cardiovascular Medicine specializing in cardiovascular imaging (MRI/CT), cardio-oncology, and multi-omics technologies.
  • Dr. Lisa Rotenstein – Primary care physician at UCSF Health; Director of the Center to Advance Digital Physician Practice Transformation and Assistant Professor of Medicine.
  • Dr. James Thomas – Cardiologist; Director of the Center for Heart Valve Disease and Professor of Medicine at Northwestern University Feinberg School of Medicine.

“Our Clinical Advisory Board brings together leading voices across the healthcare continuum. These are physicians innovating in their own practices and pushing the boundaries of what’s possible with technology,” said Connor Landgraf, CEO and Co-Founder of Eko Health. “As we advance AI-powered detection tools, their insights will help us build responsibly, scale effectively, and stay focused on improving patient care.”

This announcement follows a series of significant clinical milestones for Eko, including FDA clearances for its Low Ejection Fraction and Structural Murmur detection algorithms, the publication of peer-reviewed validation studies in Nature Medicine, The Lancet Digital Health and JACC: Advances, and the introduction of a new Category III CPT® code effective July 1, 2025. These developments reinforce Eko’s leadership in AI-powered cardiac detection and its mission to transform the delivery of cardiopulmonary care.

About Eko Health
Eko Health is a pioneering AI early disease detection company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes & ECG devices, patient and provider software, and AI-powered analysis. Its FDA-cleared platform, with over 650,000 devices sold to providers globally, allows them to detect earlier and with higher accuracy, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California.

For more information about Eko Health, visit ekohealth.com.

Media Contact:
 Sam Moore
 Eko Health
 sam.moore@ekohealth.com

©2025 Eko Health, Inc. All rights reserved. MKT-0003868

View original content to download multimedia:https://www.prnewswire.com/news-releases/eko-health-expands-clinical-advisory-board-to-advance-ai-powered-disease-detection-302522616.html

SOURCE Eko Health

Staff

Recent Posts

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

2 minutes ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

2 minutes ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

2 minutes ago

Shrub Oak International School Reinforces Unwavering Commitment to Student Safety and Security

MOHEGAN LAKE, N.Y., Dec. 5, 2025 /PRNewswire/ -- Shrub Oak International School today announced enhanced…

2 minutes ago

‘I’D RATHER GET A ROOT CANAL’: US WORKERS DREAD THE OFFICE HOLIDAY PARTY

National poll reveals 27% of workers prefer dental work over office celebrations as workplace disconnection…

2 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA…

2 minutes ago